- Home
- CHRS vs FMN Comparison
CHRS vs FMN Comparison
Compare CHRS & FMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FMN
- Stock Information
- Founded
- CHRS 2010
- FMN 2002
- Country
- CHRS United States
- FMN United States
- Employees
- CHRS N/A
- FMN N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FMN Investment Managers
- Sector
- CHRS Health Care
- FMN Finance
- Exchange
- CHRS Nasdaq
- FMN Nasdaq
- Market Cap
- CHRS 134.4M
- FMN 127.6M
- IPO Year
- CHRS 2014
- FMN N/A
- Fundamental
- Price
- CHRS $1.07
- FMN $11.28
- Analyst Decision
- CHRS Strong Buy
- FMN
- Analyst Count
- CHRS 4
- FMN 0
- Target Price
- CHRS $5.38
- FMN N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- FMN 22.8K
- Earning Date
- CHRS 03-12-2025
- FMN 01-01-0001
- Dividend Yield
- CHRS N/A
- FMN 3.86%
- EPS Growth
- CHRS N/A
- FMN N/A
- EPS
- CHRS N/A
- FMN N/A
- Revenue
- CHRS $304,340,000.00
- FMN N/A
- Revenue This Year
- CHRS $2.07
- FMN N/A
- Revenue Next Year
- CHRS N/A
- FMN N/A
- P/E Ratio
- CHRS N/A
- FMN N/A
- Revenue Growth
- CHRS 44.19
- FMN N/A
- 52 Week Low
- CHRS $0.66
- FMN $9.09
- 52 Week High
- CHRS $2.65
- FMN $11.31
- Technical
- Relative Strength Index (RSI)
- CHRS 39.03
- FMN 60.55
- Support Level
- CHRS $1.06
- FMN $11.01
- Resistance Level
- CHRS $1.16
- FMN $11.30
- Average True Range (ATR)
- CHRS 0.08
- FMN 0.09
- MACD
- CHRS 0.00
- FMN 0.02
- Stochastic Oscillator
- CHRS 5.56
- FMN 72.97
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers.. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.